CMN Weekly (17 January 2025) - Your Weekly CRISPR...
CMN Weekly
Jan. 17, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Profluent Bio
Company Type: Therapeutic development
Main focus: Using AI to optimise the design of gene editors for novel therapeutics
Company stage: Pre-clinical
Diseases:
Genome-editing tool: OpenCRISPR-1
Funding stage: Venture - Series Unknown
Location: Berkeley, California, USA
Website: https://www.profluent.bio/
Pipeline:
Partners:
Profluent Bio is a biotechnology startup focused on leveraging AI to optimise protein engineering for gene editing. The company's principal project, OpenCRISPR, aims to revolutionise CRISPR technology by designing novel, AI-generated CRISPR proteins. OpenCRISPR is the world’s first open source, AI generated gene editor and has demonstrated precision editing of the human genome. OpenCRISPR-1 launched earlier this year as an open-source, freely available to licence, customisable gene editor designed with AI.
